You are here: Industry Insights > migraine drug

News List

New Migraine Drug, Rimegepant (Not Yet Approved) Might Help When Other Meds Don't drugs
July 11, 2019
A new migraine drug might offer an alternative to people who do not get relief from current medications, a new trial suggests.
Novartis and Amgen dispute over migraine drug reaches court pharmaceutical-technology
April 09, 2019
Novartis and Amgen dispute over migraine drug reaches court
Teva’s migraine drug secures European marketing approval pharmaceutical-technology
April 03, 2019
Israel’s Teva Pharmaceutical has received marketing authorisation from the European Commission (EC) for Ajovy (fremanezumab), an injection intended to provide relief from migraines.
Novartis migraine drug not cost effective: UK price watchdog expressbpd
January 14, 2019
Novartis, which pledged to work with NICE to address outstanding questions, said patients would lack new treatment options if the decision remains unchanged
NICE declines to endorse Novartis’ pricey migraine drug Aimovig pharmaceutical-technology
January 14, 2019
National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine prevention drug Aimovig (erenumab) saying the drug is not a cost-effective use of the NHS resources.....
Impel raises $67.5M as it eyes filing for nasal migraine drug fiercebiotech
December 29, 2018
Impel NeuroPharma’s championing of the nasal delivery route for drugs has been rewarded with a fourth-round financing that will help it advance three projects through the clinic.....
Strides’ subsidiary inks pact with SUDA Pharmaceuticals for migraine drug expressbpd
November 10, 2018
Under the terms of agreement, SUDA will receive an upfront cash payment of $ 0.4 million and a further payment of $ 0.6 million on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the U
Teva confident in September approval for migraine drug despite latest Celltrion plant citation fiercepharma
August 09, 2018
The FDA has reinspected a Celltrion plant in South Korea after issuing it a warning letter earlier in the year. Although the July visit resulted in another FDA Form 483, Teva officials are confident the findings will not delay the expected approval next m
Novartis' migraine drug gets EMA approval pharmatimes
August 01, 2018
The EMA has approved Norvartis’ Aimovig (erenumab), making it Europe’s first treatment specifically designed to prevent migraine.
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig fiercepharma
July 04, 2018
Amgen and Novartis’ Aimovig, first in its new class of migraine meds, hit the scene in May. Patients were ready and waiting for it.

Previous page 1 2 Next page